Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma;Traitement adjuvant du cancer du sein par le tamoxifne: Réflexions sur le risque de carcinosarcome utérin

Gynecologie Obstetrique et Fertilite

Volumn 37, Issue 5, 2009, Pages 447-451

  Leung, F ^a,b   Terzibachian, J J ^b   Govyadovskiy, A ^b   Bourtembourg, A ^a   Maillet, R ^a   Riethmuller, D ^a  

^a HÔPITAL SAINT JACQUES   (France)

^b Centre Hospitalier de Belfort   (France)

Author keywords

Aromatase inhibitors; Breast cancer; Tamoxifen; Uterine carcinosarcoma

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG USE; HUMAN; OUTCOME ASSESSMENT; REVIEW; UTERINE CARCINOSARCOMA; UTERUS CARCINOMA;

EID: 67349207121     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2009.03.010     Document Type: Note

References (34)

1. M.J.E. Mourits, E.G. De Vries, P.H.B. Willemse, K.A. Ten Hoor, H. Hollema, and A.G. Van der Zee Tamoxifen treatment and gynecologic side effects: a review Obstet Gynecol 97 2001 855 866 (Pubitemid 32406196)
2. I. Cohen Endometrial pathologies associated with postmenopausal tamoxifen treatment Gynecol Oncol 94 2004 256 266 (Pubitemid 39024525)
3. F.E. Van Leeuwen, J. Benraadt, and J.W.W. Coebergh Risk of endometrial cancer after tamoxifen treatment of breast cancer Lancet 343 1994 448 452 (Pubitemid 24059587)
4. A.J. Swerdlow, M.E. Jones The British tamoxifen second cancer study group Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study J Natl Cancer Inst 97 2005 375 384 (Pubitemid 40425956)
5. (EBCTCG) Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
6. M.A. Killackey, T.B. Hakes, and V.K. Pierce Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens Cancer Treat Rep 69 1985 237 238 (Pubitemid 15170469)
7. P. Pautier Sarcomes utérins Oncologie 9 2007 137 143 (Pubitemid 46651103)
8. F. Leung, J.J. Terzibachian, Z. Aouar, A. Govyadovskiy, and C. Lassabe Sarcomes utérins : aspects cliniques et histopathologiques. A propos de 15 cas Gynecol Obstet Fertil 36 2008 628 635
9. W.G. McCluggage Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas ? J Clin Pathol 55 2002 321 325 (Pubitemid 34494168)
10. M.G. McCluggage Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas Int J Gynecol Cancer 12 2002 687 690
11. S. Acharya, M.L. Hensley, A. Montag, and G.F. Fleming Rare uterine cancers Lancet Oncol 6 2005 961 971 (Pubitemid 41685229)
12. W.G. McCluggage, U. Haller, and R.J. Kurman Mixed epithelial and mesenchymal tumours F.A. Tavassoli P. Devilee World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs 2003 IARC Press Lyon 245 249
13. L. Hardell Tamoxifen as risk factor for carcinoma of corpus uteri Lancet 2 1988 563 (Pubitemid 18213858)
14. Leung F, Terzibachian JJ, Govyadovskiy A, et al. Carcinosarcomes utérins associés au traitement par le tamoxifne. propos de deux cas et revue de la littérature. J Gynecol Obstet Biol Reprod 2009, doi:10.1016/j.jgyn.2008.11.005.
15. L. Bernstein, D. Deapen, and J.R. Cerhan Tamoxifen therapy for breast cancer and endometrial cancer risk J Natl Cancer Inst 91 1999 1654 1662 (Pubitemid 29479933)
16. L. Bergman, M.L.R. Beelen, M.P.W. Gallee, H. Hollema, J. Benraadt, and F.E. van Leeuwen Risk and prognosis of endometrial cancer after tamoxifen for breast cancer Lancet 356 2000 881 887
17. I. Treilleux, H. Mignotte, and C. Clement-Chassagne Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: report of six cases and review of the literature Eur J Surg Oncol 25 1999 477 482 (Pubitemid 29462336)
18. W.G. McCluggage, M. Abdulkader, and J.H. Price Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases Int J Gynecol Cancer 10 2000 280 284
19. J. Varela-Duran, L.E. Nochomovitz, K.A. Prem, and L.P. Dehner Postirradiation Mixed Mullerian Tumors of the uterus. A comparative clinicopathologic study Cancer 45 1980 1625 1631 (Pubitemid 10145010)
20. R.F. Meredith, D.R. Eisert, Z. Kaka, S.E. Hodgson, G.A. Johnston Jr., and J.G. Boutselis An excess of uterine sarcomas after pelvic irradiation Cancer 58 1986 2003 2007 (Pubitemid 16008775)
21. H. Mignotte, C. Lasset, and V. Bonadona Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study Int J Cancer 76 1998 325 330 (Pubitemid 28282929)
22. J. Bonneterre, A. Buzdar, J.F. Robertson, and B. Thurlimann Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247 2258
23. J.M. Nabholtz Aromatase inhibitors in the management of early breast cancer Eur J Surg Oncol 34 2008 1199 1207
24. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
25. A. Coates, A. Keshaviah, and B. Thurlimann Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer: update of study BIG 1-98 J Clin Oncol 25 2007 486 492 (Pubitemid 350002953)
26. R.C. Coombes, E. Hall, and L.J. Gibson A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092 (Pubitemid 38298988)
27. R.C. Coombes, L.S. Kilburn, and C. Snowdon Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial Lancet 369 2007 359 370
28. P.E. Goss, J.N. Ingle, and S. Martino A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793 1802 (Pubitemid 37362955)
29. R. Jakesz, R. Greil, and M. Gnant Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG 6a) J Natl Cancer Inst 99 2007 1845 1853
30. P. Morice, A. Rodrigues, and P. Pautier Chirurgie des sarcomes utérins: revue de la littérature et recommandations sur la prise en charge chirurgicale Gynecol Obstet Fertil 31 2003 147 150 (Pubitemid 36548054)
31. A. Gadducci, S. Cosio, A. Romanini, and A.R. Genazzani The management of uterine sarcoma: a debated clinical challenge Crit Rev Oncol Hematol 65 2007 129 142
32. E.S. Podczaski, C.A. Woomert, C.W. Stevens, A. Manetta, J.E. Larson, R.J. Zaino, and R. Mortel Management of malignant mixed mesodermal tumours of the uterus Gynecol Oncol 32 1989 240 244 (Pubitemid 19041970)
33. N.S. Reed, C. Mangioni, and H. Malmström Phase III randomised study to evaluate the role of adjuvant radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874) Eur J Cancer 44 2008 808 818
34. A.H. Wolfson, M.F. Brady, and T. Rocereto A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus Gynecol Oncol 107 2007 177 185 (Pubitemid 47575740)